

PD-L1xVEGF Space – besides Merck, no one has made a move yet – but the landscape is getting more crowded

	 MERCK	 Bristol Myers Squibb	<i>REGENERON</i>	 BeiGene	 Roche	AstraZeneca 	 MERCK
Approved PD-(L)1	Keytruda (PD-1)	Opdivo (PD-1)	Libtayo (PD-1)	Tevimbra (PD-1)	Tecentriq (PD-L1)	Imfinzi (PD-L1)	Bavencio (PD-L1)
Peak Sales / LOE	\$30B / 2028	\$8B / 2028	\$2.5B / 2035	\$1.5B / 2033	\$6B / 2030	\$7B / 2031	<\$1B / 2036
Key Tumors	NSCLC, Melanoma, HNSCC, TNBC, CRC, HCC, RCC, GC, CC, MCC, BTC, BC, EC, EAC, TMB-H, MSI-H, HL, NHL	NSCLC, Melanoma, HNSCC, CRC, HCC, RCC, GC, BC, EAC, MESO, HL	NSCLC, BC, cSCC	EAC	NSCLC, HCC, Melanoma, SCLC, ASPS	NSCLC, HCC, SCLC, BTC	BC, RCC, MCC
Presence?	Yes (LM-290)  LaNova 礼新医药	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed

sleuthinsights.com

Eligible Partners – China (non-exhaustive)


SSGJ-707
(Ph2)


AP505 (Ph2)


MHB039A
(Ph1/2)


RC148 (Ph1)


DR30206
(Ph1)


CVL006
(Ph1)


SCTB14
(Ph1/2)


JS207 (Ph1)


HC010 (Ph1)


SG1408
(Ph1)

Eligible Partners – ex-China (non-exhaustive)


NY-500 (PC)


PD-L1/VEGF
Trap (PC)


CR-001 (PC)


Jankistomig
(PC)


AI-081
(Ph1/2)

Other ex-China / China Partnerships


IMM2510
(Ph3)
In-licensed


BNT327
(Ph3)
Acquired


Ivonescimab
(Ph3)
In-licensed

Note: NSCLC = non-small cell lung cancer; HNSCC = head and neck squamous cell carcinoma; TNBC = triple negative breast cancer; CRC = colorectal cancer; HCC = hepatocellular carcinoma; RCC = renal cell carcinoma; SCLC = small cell lung cancer; GC = gastric cancer; CC = cervical cancer; MCC = Merkel cell carcinoma; BTC = biliary tract cancer; BC = bladder cancer; EC = endometrial carcinoma; EAC = esophagus cancer; TMB-H = tumor-mutational burden-high cancer; MSI-H = microsatellite instability-high; MESO = mesothelioma; ASPS = alveolar soft part sarcoma; cSCC cutaneous squamous cell carcinoma; OC = ovarian cancer; NEN = neuroendocrine neoplasm; PC = pancreatic cancer; HL = Hodgkin’s lymphoma; NHL = non-Hodgkin’s lymphoma